Heather Moore, BCOP, CPP, PharmD

Pharmacists manage QTc monitoring with ribociclib, confirm QTcF, assess interactions, hold and dose-reduce therapy, and guide CDK4/6 switches for toxicity or cost.

Learn how pharmacists spot and manage ribociclib QTc prolongation, handle drug interactions, and switch CDK4/6 inhibitors for safety and cost.

Multidisciplinary breast cancer care boosts CDK4/6 adherence with nurse and pharmacy check-ins, targeted toxicity scripts, and early intervention to prevent drop-offs.

How multidisciplinary breast cancer teams use nurses and specialty pharmacists to catch CDK4/6 inhibitor toxicities early and keep patients on therapy.

Learn how CDK4/6 inhibitor schedules vary and how pharmacists boost adherence, manage nausea, labs, QTc, and drug interactions.

How CDK4/6 inhibitors stack up in metastatic HR+ breast cancer, with trial survival data, real‑world tolerability, and visceral crisis caveats.

Learn how teams flag adjuvant CDK4/6 candidates at diagnosis, avoid patients slipping through cracks, and improve real-world use.

Five-year NATALEE updates show ribociclib boosts invasive disease-free survival in broader early breast cancer risk groups, guiding therapy choice.

The panelists examined the 5-year follow-up data from the NATALEE trial, which evaluated the addition of ribociclib to a nonsteroidal aromatase inhibitor in patients with early breast cancer. Faculty examined how the patient population, study design, and clinical endpoints in this trial differed from those used in the monarchE trial. The discussion highlighted important distinctions in eligibility criteria and outcome measures that may influence interpretation of results. Experts reviewed the key efficacy findings from the 5-year analysis and discuss the safety profile observed with ribociclib in the adjuvant setting. Particular attention was given to how these outcomes inform the role of CDK4/6 inhibition in early-stage disease. Faculty shared their perspectives on the most meaningful clinical takeaways from the updated data. Finally, the panel compared the findings from NATALEE with the long-term results from monarchE and discuss how these studies together may shape treatment strategies and decision-making in clinical practice.

Throughout the conversation, the experts provide a comprehensive reflection on the field and the factors that may shape how clinicians approach care moving forward.

Panelists discuss how unmet needs in early and metastatic breast cancer include overcoming endocrine resistance, improving adverse effect management, ensuring guideline-concordant care, addressing long-term toxicities, and expanding the role of pharmacists in monitoring, clinical trial integration, and advancing the evolving CDK4/6 inhibitor pipeline.

Panelists discuss how pharmacists and multidisciplinary teams can empower patients with early or metastatic breast cancer through education, adverse effect management, dose adjustments, frequent follow-up, and integration of CDK4/6 inhibitors with other therapies, while addressing logistical and clinical challenges in practice.

Panelists discuss how differences in dosing schedules, adherence challenges, and total duration of CDK4/6 inhibitor therapy impact patient management, treatment decisions, and quality of life in both advanced and early-stage settings.

Panelists discuss how dose reductions for CDK4/6 inhibitors are commonly needed due to neutropenia, thrombocytopenia, diarrhea, and other toxicities but do not compromise efficacy based on subgroup analyses from major trials, while dose escalation strategies (particularly starting abemaciclib at 50 mg and gradually increasing) have been successfully implemented based on the TRADE study data to reduce early discontinuation rates by approximately 50%, though practical challenges exist with pharmacy dispensing and patient questions about why escalation to full dose is necessary when lower doses maintain efficacy.

Panelists discuss how evaluating quality of life in patients on CDK4/6 inhibitors requires asking open-ended questions beyond just adverse effects to assess social functioning, work capacity, and emotional well-being (with quality of life data showing these agents maintain rather than significantly improve outcomes), and how multidisciplinary care can be optimized through nurse navigators for additional patient touchpoints, coordination with subspecialty colleagues like pulmonology and cardio-oncology for rare toxicities, and utilizing learners and standardized workflows to manage the high patient volume despite limited pharmacist resources.

Panelists discuss how treatment sequencing in early-stage breast cancer requires a stepwise approach, adding one therapy at a time (typically radiation, then hormonal therapy, then CDK4/6 inhibitors, with special considerations for BRCA-positive patients receiving olaparib first), while in metastatic settings the sequencing is more straightforward with first-line CDK4/6 inhibitors plus endocrine therapy, and how patient adherence can be optimized through shared decision-making, detailed toxicity education with graded explanations, frequent health care team touchpoints especially during the challenging first 90 days, and addressing the unique adherence challenges in early-stage patients who are asymptomatic compared to metastatic patients.

Panelists discuss how analysis from the Miami Breast Cancer Conference showing 60% of eligible early breast cancer patients are not receiving CDK4/6 inhibitors reflects disparities between academic and community settings, particularly affecting older patients and those with fewer lymph nodes, while identifying remaining unmet needs including better management of quality-of-life impacting adverse effects like fatigue and diarrhea, reducing the burden of frequent laboratory monitoring, and addressing financial toxicity and administrative barriers that affect both patients and health care staff.

Panelists discuss how they are excited about future CDK4/6 inhibitor data including oral SERDs to replace fulvestrant injections, triplet combinations with newer agents, expansion into HER2-positive settings, and the potential role of ctDNA monitoring, while emphasizing key patient education points such as explaining mechanism of action differences from chemotherapy, managing expectations about common adverse effects, setting parameters for when to contact the care team, and providing resources like ChemoCare while also educating health care teams through primary literature and electronic health record care plans.

Panelists discuss how pharmacists play a crucial role in toxicity management and monitoring for CDK4/6 inhibitors (including proper QTc calculations, lab monitoring thresholds, and diarrhea mitigation strategies), how they incorporate NCCN guideline recommendations into clinical practice while identifying patients who might fall through the cracks (especially those not receiving chemotherapy), and how they consider sequencing CDK4/6 inhibitors based on postMONARCH trial data for patients with soft progression or low tumor burden without actionable mutations.

Panelists discuss how treatment selection between CDK4/6 inhibitors in early-stage breast cancer is primarily driven by trial eligibility criteria with abemaciclib being preferred when qualified, while in metastatic settings ribociclib is often favored due to overall survival data, and how adverse event profiles differ significantly among the 3 agents (neutropenia with palbociclib/ribociclib, QTc prolongation and drug interactions with ribociclib, and early-onset diarrhea with abemaciclib that typically improves with supportive care management).

Pharmacists play a crucial role in managing drug interactions and optimizing treatment with CDK4/6 inhibitors for HER2-positive breast cancer patients.

Panelists discuss how CDK4/6 inhibitors can be considered for patients with visceral crisis based on limited data from the RIGHT Choice trial (though historically chemotherapy has been preferred), and how the number of positive lymph nodes in early-stage breast cancer drives treatment selection based on the specific inclusion criteria from the monarchE and NATALEE trials, with dual-eligible patients requiring consideration adverse effect profiles and patient-specific factors.

Panelists discuss how FDA-approved CDK4/6 inhibitors are used in early breast cancer (abemaciclib and ribociclib with different trial designs and dosing regimens) and metastatic breast cancer (palbociclib, ribociclib, and abemaciclib showing approximately 2-year progression-free survival advantages in various combination therapies).

Panelists discuss how there have been many new agents being studied and released at the current time and how the development of these agents is moving at a rapid pace. The adverse effect profiles of newer antibody-drug conjugates create a greater opportunity for pharmacists to be involved in toxicity management.

Panelists discuss how optimizing antibody-drug conjugate (ADC) therapy in patients with metastatic breast cancer (mBC) requires interdisciplinary care, including oncologists, pharmacists, and nurses. Adherence barriers such as cost, access, and insurance are addressed via financial and social support.

Panelists discuss how health care professionals use clear, tailored communication to explain antibody-drug conjugate (ADC) risks, benefits, and regimens. They provide education, address concerns, and ensure adherence through counseling and shared decision-making.

Panelists discuss how health care professionals use standardized antibody-drug conjugate (ADC) pathways to guide dosing, adverse effect (AE) management, and transitions. Protocols ensure monitoring, toxicity mitigation, and seamless shifts between therapies for optimal care.

Panelists discuss how pharmacists should monitor neutropenia, diarrhea, and mucositis from sacituzumab govitecan (SG); interstitial lung disease (ILD) and neutropenia from trastuzumab deruxtecan (T-DXd); and neutropenia and ILD from datopotamab deruxtecan (Dato-DXd). Proactive management is essential for patient safety.

Panelists discuss how antibody-drug conjugates (ADCs) often cause toxic adverse events (AEs). Supportive care includes antiemetics, corticosteroids, and growth factors. Infusion reactions are managed with premedication and slow titration.

Panelists discuss how antibody-drug conjugates (ADCs) often show more diverse outcomes in real-world settings compared with clinical trials, with varying efficacy and adverse effect profiles. Key practical considerations for pharmacists include appropriate dosing based on patient factors, managing drug interactions, implementing premedication protocols to minimize adverse reactions, and providing comprehensive supportive care. Careful monitoring and individualized patient management are essential for optimal therapeutic outcomes.